March 1, 2013 7:05 AM | 1 min read
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
Palatin Technologies (NYSE: PTN) announced bremelanotide 1.25 mg and 1.75 mg doses significantly increased sexual arousal, sexual desire and the number of sexually satisfying events, and decreased associated distress in premenopausal women with female sexual dysfunction (FSD). Efficacy was seen in both women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD).[1]To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/60233-palatin-positive-data-bremelanotide-in-female-sexual-dysfunction-fsdThe data from a Phase 2B clinical trial were presented today at the International Society for the Study of Women's Sexual Health (ISSWSH) conference in New Orleans, LA. Bremelanotide is a first-in-class investigative melanocortin agonist and a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)."We are extremely pleased and excited with the trial results, which achieved clinical and statistical significance in the primary endpoint and key secondary endpoints using independently developed and validated measurement tools," stated Carl Spana, Ph.D., President and CEO of Palatin. "With an estimated 43 percent of women suffering from some form of FSD and no FDA approved therapies,
See full press release
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.